JP2008539794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008539794A5 JP2008539794A5 JP2008512536A JP2008512536A JP2008539794A5 JP 2008539794 A5 JP2008539794 A5 JP 2008539794A5 JP 2008512536 A JP2008512536 A JP 2008512536A JP 2008512536 A JP2008512536 A JP 2008512536A JP 2008539794 A5 JP2008539794 A5 JP 2008539794A5
- Authority
- JP
- Japan
- Prior art keywords
- biological sample
- level
- therapeutic agent
- biomarker
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68258205P | 2005-05-18 | 2005-05-18 | |
| US60/682,582 | 2005-05-18 | ||
| US74928505P | 2005-12-09 | 2005-12-09 | |
| US60/749,285 | 2005-12-09 | ||
| PCT/US2006/019414 WO2006125143A2 (en) | 2005-05-18 | 2006-05-18 | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012272271A Division JP2013057686A (ja) | 2005-05-18 | 2012-12-13 | Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008539794A JP2008539794A (ja) | 2008-11-20 |
| JP2008539794A5 true JP2008539794A5 (https=) | 2009-09-24 |
| JP5208730B2 JP5208730B2 (ja) | 2013-06-12 |
Family
ID=37022828
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512536A Expired - Fee Related JP5208730B2 (ja) | 2005-05-18 | 2006-05-18 | Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法 |
| JP2012272271A Pending JP2013057686A (ja) | 2005-05-18 | 2012-12-13 | Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012272271A Pending JP2013057686A (ja) | 2005-05-18 | 2012-12-13 | Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8337851B2 (https=) |
| EP (1) | EP1894012A2 (https=) |
| JP (2) | JP5208730B2 (https=) |
| AU (1) | AU2006247067B2 (https=) |
| CA (1) | CA2608751A1 (https=) |
| WO (1) | WO2006125143A2 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006125143A2 (en) * | 2005-05-18 | 2006-11-23 | Novartis Ag | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
| WO2007067032A1 (en) | 2005-12-09 | 2007-06-14 | Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| EP1974017B2 (en) | 2005-12-09 | 2023-06-21 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Means and methods for influencing the stability of antibody producing cells |
| WO2007082379A2 (en) * | 2006-01-20 | 2007-07-26 | Mcgill University | Method to identify cd40-sensitive cells using gene expression |
| MX2008013508A (es) | 2006-04-21 | 2008-10-31 | Novartis Ag | Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40. |
| EP1862802B1 (en) * | 2006-06-01 | 2008-12-10 | Cellzome Ag | Methods for the identification of ZAP-70 interacting molecules and for the purification of ZAP-70 |
| MX2010005080A (es) | 2007-11-07 | 2010-07-28 | Genentech Inc | Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40. |
| KR101787768B1 (ko) * | 2009-04-18 | 2017-10-18 | 제넨테크, 인크. | 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 |
| WO2010127186A1 (en) | 2009-04-30 | 2010-11-04 | Prognosys Biosciences, Inc. | Nucleic acid constructs and methods of use |
| JP5781508B2 (ja) | 2009-07-15 | 2015-09-24 | アイム・セラピューティクス・べー・フェー | 高親和性抗体を産生させるための手段および方法 |
| KR101572463B1 (ko) * | 2009-08-25 | 2015-11-27 | 베르그 엘엘씨 | 에피메타볼릭 쉬프터(조효소 ｑ10)를 사용하는 육종의 치료 방법 |
| US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| HRP20151294T1 (hr) | 2010-04-05 | 2016-03-11 | Prognosys Biosciences, Inc. | Biološka testiranja sa prostornim kodiranjem |
| US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
| AU2011242990B2 (en) * | 2010-04-19 | 2015-02-12 | Biomarker Strategies, Llc. | Compositions and methods for prediction of drug sensitivity, resistance, and disease progression |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| EP2646466B1 (en) * | 2010-12-02 | 2017-03-29 | AIMM Therapeutics B.V. | Means and methods for producing high affinity antibodies |
| EP2694709B1 (en) | 2011-04-08 | 2016-09-14 | Prognosys Biosciences, Inc. | Peptide constructs and assay systems |
| GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
| CN113461819B (zh) | 2011-04-29 | 2024-01-02 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
| WO2014060483A1 (en) | 2012-10-17 | 2014-04-24 | Spatial Transcriptomics Ab | Methods and product for optimising localised or spatial detection of gene expression in a tissue sample |
| AU2013337903B2 (en) | 2012-10-30 | 2018-08-16 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
| HK1221013A1 (zh) | 2013-03-15 | 2017-05-19 | 普罗格诺西斯生物科学公司 | 用於检测肽/mhc/tcr结合的方法 |
| EP3013983B1 (en) | 2013-06-25 | 2023-02-15 | Prognosys Biosciences, Inc. | Spatially encoded biological assays using a microfluidic device |
| WO2015070037A2 (en) | 2013-11-08 | 2015-05-14 | Prognosys Biosciences, Inc. | Polynucleotide conjugates and methods for analyte detection |
| WO2015085171A1 (en) * | 2013-12-06 | 2015-06-11 | Adventist Health Systems/Sunbelt, Inc. | Role of mcp-1 in relapse of acute myeloid leukemia after hematopoietic stem cell transplantation |
| AU2015211480B2 (en) | 2014-01-31 | 2020-05-14 | Kling Biotherapeutics B.V. | Means and methods for producing stable antibodies |
| US10016159B2 (en) * | 2014-10-24 | 2018-07-10 | Koninklijke Philips N.V. | Determination of TGF-β pathway activity using unique combination of target genes |
| US10774374B2 (en) | 2015-04-10 | 2020-09-15 | Spatial Transcriptomics AB and Illumina, Inc. | Spatially distinguished, multiplex nucleic acid analysis of biological specimens |
| WO2017024019A1 (en) * | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| US11142794B2 (en) | 2015-10-05 | 2021-10-12 | UCB Biopharma SRL | Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases |
| AU2017345813B2 (en) * | 2016-10-23 | 2024-06-13 | Berkeley Lights, Inc. | Methods for screening B cell lymphocytes |
| JP2021523379A (ja) * | 2018-05-14 | 2021-09-02 | ベルゲンビオ アーエスアー | 血清バイオマーカー |
| CN112638375A (zh) | 2018-06-15 | 2021-04-09 | 旗舰创业创新五公司 | 通过后细胞信号传导因子的调节来增加免疫活性 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| EP3976820A1 (en) | 2019-05-30 | 2022-04-06 | 10X Genomics, Inc. | Methods of detecting spatial heterogeneity of a biological sample |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| US11732299B2 (en) | 2020-01-21 | 2023-08-22 | 10X Genomics, Inc. | Spatial assays with perturbed cells |
| EP4153775B1 (en) | 2020-05-22 | 2024-07-24 | 10X Genomics, Inc. | Simultaneous spatio-temporal measurement of gene expression and cellular activity |
| EP4025692A2 (en) | 2020-06-02 | 2022-07-13 | 10X Genomics, Inc. | Nucleic acid library methods |
| EP4158054B1 (en) | 2020-06-02 | 2025-04-16 | 10X Genomics, Inc. | Spatial transcriptomics for antigen-receptors |
| WO2021252499A1 (en) | 2020-06-08 | 2021-12-16 | 10X Genomics, Inc. | Methods of determining a surgical margin and methods of use thereof |
| JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
| JP2024512669A (ja) | 2021-03-31 | 2024-03-19 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用 |
| US20240316104A1 (en) | 2021-06-29 | 2024-09-26 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| CN113684180B (zh) * | 2021-08-31 | 2023-05-26 | 山东大学第二医院 | 一种提高骨髓瘤杀伤活性的nk细胞制备方法 |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| CN115845063B (zh) * | 2022-12-20 | 2024-07-09 | 中国医学科学院医学生物学研究所 | 与急性t淋巴细胞白血病治疗相关的靶点cd40lg及其应用 |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2024173352A2 (en) * | 2023-02-13 | 2024-08-22 | Shattuck Labs, Inc. | Methods of treating cancer with a sirp1a-based chimeric protein |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1079824B1 (en) * | 1998-05-19 | 2011-08-31 | RESEARCH DEVELOPMENT FOUNDATION (a Nevada corporation) | Triterpene compositions and methods for use thereof |
| AU5914201A (en) * | 2000-04-25 | 2001-11-07 | Idec Pharma Corp | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
| JP4202127B2 (ja) * | 2000-10-02 | 2008-12-24 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法 |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1575574A4 (en) * | 2002-10-30 | 2007-11-07 | Blood Res Center | METHOD FOR TREATING AND PREVENTING APOPTOSIS-BASED DISEASES BY MEANS OF RNA INTERFERENCE AGENTS |
| ES2246191T1 (es) * | 2002-12-11 | 2006-02-16 | Ventana Medical Systems, Inc. | Metodo para predecir la respuesta a la terapia dirigida a her2. |
| GB0301566D0 (en) * | 2003-01-23 | 2003-02-26 | Eirx Therapeutics Ltd | Kinasaes and GPCRs involved in apoptosis |
| EP1844815B1 (en) * | 2003-11-04 | 2011-09-14 | Novartis Vaccines and Diagnostics, Inc. | Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers |
| PT1694360E (pt) * | 2003-11-04 | 2010-12-13 | Novartis Vaccines & Diagnostic | Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos |
| US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| CA2554735A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| US20070292439A1 (en) * | 2004-04-27 | 2007-12-20 | Novartis Vaccines And Diagnostics, Inc. | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| WO2006125143A2 (en) * | 2005-05-18 | 2006-11-23 | Novartis Ag | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
-
2006
- 2006-05-18 WO PCT/US2006/019414 patent/WO2006125143A2/en not_active Ceased
- 2006-05-18 JP JP2008512536A patent/JP5208730B2/ja not_active Expired - Fee Related
- 2006-05-18 CA CA002608751A patent/CA2608751A1/en not_active Abandoned
- 2006-05-18 US US11/914,714 patent/US8337851B2/en not_active Expired - Fee Related
- 2006-05-18 AU AU2006247067A patent/AU2006247067B2/en not_active Ceased
- 2006-05-18 EP EP06770643A patent/EP1894012A2/en not_active Withdrawn
-
2012
- 2012-12-13 JP JP2012272271A patent/JP2013057686A/ja active Pending
- 2012-12-17 US US13/717,175 patent/US20130230528A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008539794A5 (https=) | ||
| Lim et al. | Inflammatory breast cancer biology: the tumour microenvironment is key | |
| Bertrand et al. | TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma | |
| Padro et al. | Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia | |
| Rassouli et al. | Systemic inflammatory markers as independent prognosticators of head and neck squamous cell carcinoma | |
| Jones et al. | Cytokines in cancer drug resistance: Cues to new therapeutic strategies | |
| Mantovani et al. | Tumour-associated macrophages as treatment targets in oncology | |
| Koornstra et al. | Expression of TRAIL (TNF‐related apoptosis‐inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas | |
| JP2008539791A5 (https=) | ||
| JP5409628B2 (ja) | 抗ｔｗｅａｋ受容体抗体の治療上の使用 | |
| DK2535716T3 (en) | Cancer marker and therapeutic target | |
| Rizzo et al. | New insights into the molecular pathogenesis of langerhans cell histiocytosis | |
| Yin et al. | RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response | |
| KR102739338B1 (ko) | 아데노신 경로 활성화를 갖는 암의 검출 및 치료 방법 | |
| Lassen et al. | A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers | |
| Devan et al. | Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma | |
| CN112955748A (zh) | 治疗癌症的方法 | |
| WO2012082742A2 (en) | Detecting cancer with anti-ccl25 and anti-ccr9 antibodies | |
| WO2013103637A1 (en) | Analysis and targeting of ror2 in cancer | |
| JP2024511373A (ja) | がんのためのバイオマーカーおよびその使用 | |
| Ye et al. | Enavatuzumab, a humanized anti‐TWEAK receptor monoclonal antibody, exerts antitumor activity through attracting and activating innate immune effector cells | |
| CN112424608A (zh) | 用于疾病的预后和管理的方法 | |
| Wada et al. | Expression of BAFF‐R and TACI in reactive lymphoid tissues and B‐cell lymphomas | |
| Bedewy et al. | CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma | |
| EP2898330B1 (en) | Predicting the sensitivity of a subject to chemotherapy |